Bin Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bin Liang has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Bin Shang
Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, China
1 shared publication - Daowei Li
Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital, China
1 shared publication - Hancheng Wu
Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
1 shared publication - Huaichen Li
Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People’s Republic of China
1 shared publication - Jing Li
Department of Respiratory and Critical Care Medicine, Shandong Provincial Public Health Clinical Center, Jinan, Shandong, China
1 shared publication Jin‐Yue Liu
Department of Intensive Care Unit Shandong Provincial Third Hospital Jinan China
1 shared publication
Latest Publications
- Open Access
- 23 September 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (20)
FXR shapes an immunosuppressive microenvironment in PD-L1lo/– non-small cell lung cancer by upregulating HVEM
Immune checkpoint therapy has changed cancer treatment, including non-small cell lung cancer (NSCLC). The unresponsiveness of PD-L1 lo/– tumors to anti–PD-1/PD-L1 immunotherapy is attributed to alternative immune evasion mechanisms that remain elusive. We previously reported that farnesoid X receptor (FXR) was increased in PD-L1 lo/– NSCLC. Herein, we found that immune checkpoint HVEM was positively correlated with FXR but inversely correlated with PD-L1 in NSCLC. HVEM was highly expressed in FXR hi PD-L1 lo NSCLC. Consistently, clinically relevant FXR antagonist dose-dependently inhibited HVEM expression in NSCLC. FXR inhibited cytokine production and cytotoxicity of cocultured CD8 + T cells in vitro, and it shaped an immunosuppressive tumor microenvironment (TME) in mouse tumors in vivo through the HVEM/BTLA pathway. Clinical investigations show that the FXR/HVEM axis was associated with immunoevasive TME and inferior survival outcomes in patients with NSCLC. Mechanistically, FXR upregulated HVEM via transcriptional activation, intracellular Akt, Erk1/2 and STAT3 signals, and G1/S cycle progression in NSCLC cells. In vivo treatment experiments demonstrated that anti-BTLA immunotherapy reinvigorated antitumor immunity in TME, resulting in enhanced tumor inhibition and survival improvement in FXR hi PD-L1 lo mouse Lewis lung carcinomas. In summary, our findings establish the FXR/HVEM axis as an immune evasion mechanism in PD-L1 lo/– NSCLC, providing translational implications for future immunotherapy in this subgroup of patients.
- 23 September 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (20)
Open AccessFXR shapes an immunosuppressive microenvironment in PD-L1lo/– non-small cell lung cancer by upregulating HVEM
Immune checkpoint therapy has changed cancer treatment, including non-small cell lung cancer (NSCLC). The unresponsiveness of PD-L1 lo/– tumors to anti–PD-1/PD-L1 immunotherapy is attributed to alternative immune evasion mechanisms that remain elusive. We previously reported that farnesoid X receptor (FXR) was increased in PD-L1 lo/– NSCLC. Herein, we found that immune checkpoint HVEM was positively correlated with FXR but inversely correlated with PD-L1 in NSCLC. HVEM was highly expressed in FXR hi PD-L1 lo NSCLC. Consistently, clinically relevant FXR antagonist dose-dependently inhibited HVEM expression in NSCLC. FXR inhibited cytokine production and cytotoxicity of cocultured CD8 + T cells in vitro, and it shaped an immunosuppressive tumor microenvironment (TME) in mouse tumors in vivo through the HVEM/BTLA pathway. Clinical investigations show that the FXR/HVEM axis was associated with immunoevasive TME and inferior survival outcomes in patients with NSCLC. Mechanistically, FXR upregulated HVEM via transcriptional activation, intracellular Akt, Erk1/2 and STAT3 signals, and G1/S cycle progression in NSCLC cells. In vivo treatment experiments demonstrated that anti-BTLA immunotherapy reinvigorated antitumor immunity in TME, resulting in enhanced tumor inhibition and survival improvement in FXR hi PD-L1 lo mouse Lewis lung carcinomas. In summary, our findings establish the FXR/HVEM axis as an immune evasion mechanism in PD-L1 lo/– NSCLC, providing translational implications for future immunotherapy in this subgroup of patients.
- 1 January 2023
- Vol. 27 (6) , 2591-2604
A prognostic model based on ferroptosis-related long non-coding RNA signatures and immunotherapy responses for non-small cell lung cancer
OBJECTIVE: Non-small cell lung cancer (NSCLC) ranks high in the incidence of malignant tumors, with limited treatment op-tions and poor prognosis. Ferroptosis is a newly discovered cell death mechanism based on iron and reactive oxygen species (ROS). The role of ferroptosis-related long non-coding RNAs (ln-cRNAs) and associated prognostic mechanisms in NSCLC require investigation.MATERIALS AND METHODS: We construct-ed a prognostic multi-lncRNA signature based on ferroptosis-related differentially expressed lncRNAs in NSCLC. The levels of ferroptosis-re-lated lncRNA in normal lung cells and lung ade-nocarcinoma cells were verified by RT-PCR.RESULTS: We identified eight differentially ex-pressed lncRNAs associated with NSCLC prog-nosis. The expression of AC125807.2, AL365181.3, AL606489.1, LINC02320, and AC099850.3 was upregulated, while SALRNA1, AC026355.1, and AP002360.1 were downregulated in NSCLC cell lines. Kaplan-Meier analysis showed that a high -risk patient group was associated with poor NS-CLC prognosis. A risk assessment model based on ferroptosis-related lncRNAs was superior to NSCLC prognosis based on traditional clinico-pathological features. Gene Set Enrichment Anal-ysis (GSEA) identified immune-and tumor -relat-ed pathways in low-risk group patients. In addi-tion, The Cancer Genome Atlas (TCGA) showed that T cell function during APC co-inhibition, APC co-stimulation, chemokine receptor (CCR), MHC class I, parainflammation, T cell co-inhibition, and check-point expression differed significant-ly between low-and high-risk groups. M6A-re-lated mRNA comparisons between these groups also revealed significant differences in ZC3H13, RBM15, and METTL3 expression.CONCLUSIONS: Our new model of ln-cRNA-associated ferroptosis effectively predict-ed NSCLC prognoses.
- 1 January 2023
- Vol. 27 (6) , 2591-2604
A prognostic model based on ferroptosis-related long non-coding RNA signatures and immunotherapy responses for non-small cell lung cancer
OBJECTIVE: Non-small cell lung cancer (NSCLC) ranks high in the incidence of malignant tumors, with limited treatment op-tions and poor prognosis. Ferroptosis is a newly discovered cell death mechanism based on iron and reactive oxygen species (ROS). The role of ferroptosis-related long non-coding RNAs (ln-cRNAs) and associated prognostic mechanisms in NSCLC require investigation.MATERIALS AND METHODS: We construct-ed a prognostic multi-lncRNA signature based on ferroptosis-related differentially expressed lncRNAs in NSCLC. The levels of ferroptosis-re-lated lncRNA in normal lung cells and lung ade-nocarcinoma cells were verified by RT-PCR.RESULTS: We identified eight differentially ex-pressed lncRNAs associated with NSCLC prog-nosis. The expression of AC125807.2, AL365181.3, AL606489.1, LINC02320, and AC099850.3 was upregulated, while SALRNA1, AC026355.1, and AP002360.1 were downregulated in NSCLC cell lines. Kaplan-Meier analysis showed that a high -risk patient group was associated with poor NS-CLC prognosis. A risk assessment model based on ferroptosis-related lncRNAs was superior to NSCLC prognosis based on traditional clinico-pathological features. Gene Set Enrichment Anal-ysis (GSEA) identified immune-and tumor -relat-ed pathways in low-risk group patients. In addi-tion, The Cancer Genome Atlas (TCGA) showed that T cell function during APC co-inhibition, APC co-stimulation, chemokine receptor (CCR), MHC class I, parainflammation, T cell co-inhibition, and check-point expression differed significant-ly between low-and high-risk groups. M6A-re-lated mRNA comparisons between these groups also revealed significant differences in ZC3H13, RBM15, and METTL3 expression.CONCLUSIONS: Our new model of ln-cRNA-associated ferroptosis effectively predict-ed NSCLC prognoses.
- Open Access
- 11 May 2021
- Published by Wiley in Thoracic Cancer
- Vol. 12 (12) , 1881-1889
Using a risk model for probability of cancer in pulmonary nodules
Background: Considering the high morbidity and mortality of lung cancer and the high incidence of pulmonary nodules, clearly distinguishing benign from malignant lung nodules at an early stage is of great significance. However, determining the kind of lung nodule which is more prone to lung cancer remains a problem worldwide.Methods: A total of 480 patients with pulmonary nodule data were collected from Shandong, China. We assessed the clinical characteristics and computed tomography (CT) imaging features among pulmonary nodules in patients who had undergone video‐assisted thoracoscopic surgery (VATS) lobectomy from 2013 to 2018. Preliminary selection of features was based on a statistical analysis using SPSS. We used WEKA to assess the machine learning models using its multiple algorithms and selected the best decision tree model using its optimization algorithm.Results: The combination of decision tree and logistics regression optimized the decision tree without affecting its AUC. The decision tree structure showed that lobulation was the most important feature, followed by spiculation, vessel convergence sign, nodule type, satellite nodule, nodule size and age of patient.Conclusions: Our study shows that decision tree analyses can be applied to screen individuals for early lung cancer with CT. Our decision tree provides a new way to help clinicians establish a logical diagnosis by a stepwise progression method, but still needs to be validated for prospective trials in a larger patient population.
- 11 May 2021
- Published by Wiley in Thoracic Cancer
- Vol. 12 (12) , 1881-1889
Open AccessUsing a risk model for probability of cancer in pulmonary nodules
Background: Considering the high morbidity and mortality of lung cancer and the high incidence of pulmonary nodules, clearly distinguishing benign from malignant lung nodules at an early stage is of great significance. However, determining the kind of lung nodule which is more prone to lung cancer remains a problem worldwide.Methods: A total of 480 patients with pulmonary nodule data were collected from Shandong, China. We assessed the clinical characteristics and computed tomography (CT) imaging features among pulmonary nodules in patients who had undergone video‐assisted thoracoscopic surgery (VATS) lobectomy from 2013 to 2018. Preliminary selection of features was based on a statistical analysis using SPSS. We used WEKA to assess the machine learning models using its multiple algorithms and selected the best decision tree model using its optimization algorithm.Results: The combination of decision tree and logistics regression optimized the decision tree without affecting its AUC. The decision tree structure showed that lobulation was the most important feature, followed by spiculation, vessel convergence sign, nodule type, satellite nodule, nodule size and age of patient.Conclusions: Our study shows that decision tree analyses can be applied to screen individuals for early lung cancer with CT. Our decision tree provides a new way to help clinicians establish a logical diagnosis by a stepwise progression method, but still needs to be validated for prospective trials in a larger patient population.